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Summary
Background.  —  Patients  with  renal  failure  (RF)  have  been  systematically  excluded  from  clinical
trials; consequently  their  outcomes  have  not  been  well  studied  in  the  setting  of  percutaneous
coronary  intervention  (PCI).
Abbreviations: ACS, Acute coronary syndrome; BMS, Bare-metal stent; CAD, Coronary artery disease; CrCl, Creatinine clearance; DES,
rug-eluting stent; MACCE, Major adverse cardiovascular and cerebrovascular events (composite of cardiovascular death, myocardial infarc-
ion, stroke and target lesion revascularization); nRF, Preserved renal function; NSTEMI, Non-ST-segment elevation myocardial infarction;
CI, Percutaneous coronary intervention; RF, Renal failure; sCAD, Stable CAD; ST, Stent thrombosis; STEMI, ST-segment elevation myocardial
nfarction; TLR, Target lesion revascularization.
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Aims.  —  To  compare  cardiovascular  outcomes  after  contemporary  PCI  in  patients  with  ver-
sus without  RF,  according  to  clinical  presentation  (ST-segment  elevation  myocardial  infarction
[STEMI], acute  coronary  syndrome  [ACS]  or  stable  coronary  artery  disease  [sCAD]).
Methods.  —  Consecutive  patients  undergoing  PCI  with  stent  were  prospectively  included  from
2007 to  2012.  RF  was  deﬁned  as  creatinine  clearance  <  60  mL/min.  The  primary  endpoint  was  all-
cause mortality;  secondary  endpoints  were  major  adverse  cardiovascular  and  cerebrovascular
events (MACCE:  composite  of  cardiovascular  death,  myocardial  infarction,  stroke  and  target
lesion revascularization  [TLR]),  TLR  and  Academic  Research  Consortium  deﬁnite/probable  stent
thrombosis (ST)  at  1  year.
Results.  —  Among  5337  patients,  23%  had  PCI  for  STEMI,  34%  for  ACS  and  43%  for  sCAD,  while
27% had  RF.  RF  patients  had  a  higher  unadjusted  death  rate  than  those  with  preserved  renal
function  (nRF)  in  all  PCI  indication  groups  (STEMI,  41%  vs.  7.5%;  ACS,  19%  vs.  6%;  sCAD,  10%
vs. 3%;  P  <  0.0001  for  all).  The  rate  of  MACCE  was  also  higher  in  RF  patients  whatever  the  PCI
indication  (STEMI,  45%  vs.  15%;  ACS,  23%  vs.  14%;  sCAD,  14%  vs.  9%;  P  <  0.05  for  all).  Rates  of  TLR
(5.5—7.4%) and  ST  (<  2.5%)  were  similar  (P  >  0.05  for  both).  sCAD-RF  and  STEMI-nRF  patients  had
similar rates  of  mortality  (P  =  0.209)  and  MACCE  (P  =  0.658).  RF  was  independently  associated
with mortality,  with  a  doubled  relative  risk  in  STEMI  versus  ACS  and  sCAD  groups  (odds  ratio  5.3,
95% conﬁdence  interval  3.627—7.821  vs.  2.1,  1.465—3.140  and  2.3,  1.507—3.469,  respectively;
P <  0.0001).
Conclusion.  —  RF  is  a  stronger  independent  predictor  of  death  after  PCI  in  STEMI  than  in  ACS  or
sCAD patients.  sCAD-RF  and  STEMI-nRF  patients  had  similar  prognoses.
© 2015  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Contexte.  —  Les  patients  insufﬁsants  rénaux  chroniques  sont  systématiquement  exclus  des
études cliniques  ;  de  ce  fait,  leur  pronostic  après  angioplastie  coronaire  reste  mal  connu.
Objectif.  —  Comparer  les  événements  cardiovasculaires  après  angioplastie  contemporaine  chez
les patients  avec  versus  sans  insufﬁsance  rénale  (IR)  en  fonction  de  la  présentation  clinique
(infarctus du  myocarde  avec  élévation  du  segment  ST  [STEMI],  syndrome  coronaire  aigu  [SCA],
maladie coronaire  stable  [MCS]).
Méthodes.  —  Tous  les  patients  pris  en  charge  pour  angioplastie  coronaire  avec  implanta-
tion de  stent  ont  été  prospectivement  inclus  de  2007  à  2012.  L’IR  était  déﬁnie  par  une
clairance  de  la  créatinine  <  60  mL/min.  Le  critère  de  jugement  primaire  était  la  mortalité
toute cause  ;  les  critères  secondaires  étaient  les  MACCE  (mortalité  cardiovasculaire/infarctus
du myocarde/AVC/TLR),  TLR  (nouvelle  revascularisation  de  la  lésion  cible)  et  les  thromboses
de stent  (TS)  certaines  ou  probables  (ARC)  à  1  an.
Résultats.  —  Parmi  5337  patients,  23  %  étaient  dilatés  pour  un  STEMI,  34  %  pour  un  SCA,  43  %
pour une  MCS  et  27  %  avaient  une  IR.  Les  patients  IR  avaient  des  taux  de  mortalité  supérieurs  en
cas de  STEMI  (41  %  vs  7,5  %),  SCA  (19  %  vs  6  %)  et  MCS  (10  %  vs  3  %)  comparés  aux  patients  normo-
rénaux (p  <  0,0001  pour  tous).  Les  MACCE  étaient  également  supérieurs  quelque  soit  l’indication
d’angioplastie  (STEMI,  45  %  vs  15  %  ;  SCA,  23  %  vs  14  %  ;  MCS,  14  %  vs  9  %  ;  p  <  0,05  pour  tous).  Le
taux de  TLR  (5,5—7,4  %)  et  TS  (<  2,5  %)  étaient  comparables  (p  >  0,05  pour  les  2).  Les  patients  IR
dilatés pour  une  MCS  avaient  un  taux  de  mortalité  (p  =  0,209)  et  de  MACCE  (p  =  0,658)  compara-
bles aux  patients  STEMI  normo-rénaux.  L’IR  était  un  facteur  prédictif  indépendant  de  mortalité
avec un  sur-risque  double  en  cas  de  STEMI  versus  SCA  et  MCS  (OR  5,3,  95  %  CI  3,627—7,821  vs
2,1, 1,465—3,140  et  2,3,  1,507—3,469,  respectivement  ;  p  <  0,0001).
Conclusion.  —  L’IR  est  un  facteur  prédictif  de  surmortalité  plus  puissant  après  angioplastie  pour
un STEMI  comparé  à  un  SCA  ou  une  MCS.  Les  patients  IR  dilatés  pour  une  MCS  avaient  un  pronostic
comparable  aux  patients  STEMI  normo-rénaux.
© 2015  Elsevier  Masson  SAS.  Tous  droits  réservés.
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ackground
oronary  artery  disease  (CAD)  is  common  in  patients  with
enal  failure  (RF).  The  development  of  atherosclerotic
ardiovascular  disease  probably  begins  during  early  renal
nsufﬁciency  [1].  In  stable  CAD  (sCAD),  RF  is  an  independent
redictor  of  death  or  non-fatal  myocardial  infarction  [2].  In
cute  coronary  syndromes  (ACS),  impaired  renal  function  is
 common  ﬁnding  present  in  one  out  of  three  patients  [3].
F  in  patients  with  ACS  is  also  a  marker  of  adverse  base-
ine  clinical  characteristics  and  is  independently  associated
ith  an  increased  risk  of  death  and  myocardial  infarction
4].  After  percutaneous  coronary  intervention  (PCI),  RF  is
ndependently  associated  with  mortality  and  other  adverse
vents  in  patients  with  CAD  [5].  Patients  undergoing  PCI
or  ACS  are  known  to  have  a  poorer  short-term  prognosis
ompared  with  sCAD  patients  [6].  RF  is  an  independent  pre-
ictor  of  all-cause  mortality  for  both  ACS  and  sCAD  patients
ndergoing  PCI  [6].  Because  patients  with  RF  have  been  sys-
ematically  excluded  from  clinical  trials  [7],  the  prevalence
nd  outcomes  of  patients  with  RF  have  not  been  well  studied
n  the  PCI  setting.  To  our  knowledge,  no  paper  to  date  has
valuated  in  a  direct  manner  the  impact  of  RF  on  death  and
ther  important  outcomes  between  different  PCI  cohorts.
The  purpose  of  the  present  analysis  was  to  evaluate  car-
iovascular  outcomes  in  RF  patients  after  contemporary  PCI
ccording  to  the  indication  (ST-segment  elevation  myocar-
ial  infarction  [STEMI],  ACS  or  sCAD).
ethods
atients and  procedures
onsecutive  patients  (n  =  5337)  undergoing  PCI  with  at  least
ne  stent  were  prospectively  included  from  August  2007
o  December  2012  in  the  Middle  Care  registry  at  Pitié-
alpêtrière  Hospital.  Patients  treated  by  balloon  angioplasty
r  without  subsequent  stent  implantation  (n  =  574,  9.7%)
ere  excluded.  In  patients  undergoing  more  than  one  revas-
ularization  procedure  within  1  year  after  inclusion  (n  =  598,
1%),  subsequent  PCIs  were  counted  as  outcomes.
PCI  was  performed  by  radial  access  whenever  possi-
le  (routine  use  in  ﬁrst  intention)  using  mostly  6  French
heaths  with  systematic  stent  implantation  (unless  consid-
red  inappropriate  by  the  physician).  Antiplatelet  therapy,
ncluding  aspirin  and  a  P2Y12 inhibitor,  was  started  before
r  during  PCI,  with  a  250  mg  intravenous  dose  of  aspirin
nd  a  loading  dose  of  clopidogrel  (300—900  mg),  prasugrel
60  mg)  or  ticagrelor  (180  mg).  All  patients,  except  those
reviously  treated  by  vitamin  K  antagonists,  but  including
atients  on  new  oral  anticoagulant  drugs,  received  intra-
enous  low  molecular  weight  heparin  during  PCI  (enoxaparin
.5  mg/kg).  Glycoprotein  IIb/IIIa  inhibitors  were  admin-
stered  at  the  operator’s  discretion.  The  usual  aspirin
aintenance  dose  was  75  mg/day,  while  the  clopido-
rel  dose  was  75—150  mg/day,  the  prasugrel  dose  was
—10  mg/day  and  the  ticagrelor  dose  was  180  mg/day.  Dual
ntiplatelet  therapy  was  maintained  12  months  after  acute
oronary  syndrome,  3—12  months  after  elective  drug-eluting
tent  (DES)  implantation,  and  could  be  switched  to  single
ntithrombotic  therapy  after  1  month  after  bare-metal  stent
d
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BMS)  implantation  in  a  non-urgent  setting  [8].  Statins,  beta-
lockers  and  angiotensin-converting  enzyme  inhibitors  were
tarted  as  soon  as  possible  according  to  haemodynamic  sta-
us.
eﬁnitions
e  deﬁned  three  patient  groups  according  to  the  indica-
ion  for  PCI:  STEMI,  ACS  and  sCAD.  STEMI  was  deﬁned  by  the
resence  of  the  symptoms  of  myocardial  ischaemia,  with
ymptom  onset  to  angiography  time  <  24  hours,  associated
ith  new  ST-segment  elevation  (at  least  0.1  mV  in  two  or
ore  standard  leads  or  at  least  0.2  mV  in  two  or  more  con-
iguous  precordial  leads)  or  new  left  bundle  branch  block,
nd  associated  with  later  elevation  of  cardiac  markers  (cre-
tine  kinase  and/or  troponin  I)  at  least  three  times  above
he  upper  limit  of  normal  values.
ACS  (non-ST-segment  elevation  myocardial  infarction
NSTEMI]  or  unstable  angina)  was  deﬁned  by  the  pres-
nce  of  at  least  two  of  the  following  criteria:  symptoms
f  myocardial  ischaemia  (chest  pain  at  rest,  recent  desta-
ilization  of  previously  stable  angina  or  post-myocardial
nfarction  angina);  electrocardiographic  ST-segment  abnor-
alities  (depression  or  transient  elevation  of  ≥  0.1  mV)  or
-wave  inversion  in  at  least  two  contiguous  leads;  or  an  ele-
ated  cardiac  troponin  I  value  (above  the  upper  limit  of
ormal).  STEMI  late  presenters  (symptom  onset  to  angiog-
aphy  time  >  24  hours)  were  included  in  the  ACS  group.sCAD
ncluded  patients  with  stable  angina,  silent  ischaemia  (pos-
tive  functional  test  without  angina),  preoperative  patients
mainly  before  peripheral  vascular  surgery)  and  coronary
llograft  vasculopathy  (heart  transplant  patients  with  sig-
iﬁcant  coronary  stenosis).
RF  was  deﬁned  as  creatinine  clearance
CrCl)  <  60  mL/min/1.73  m2 using  the  Cockcroft  formula.
atients  in  each  PCI  group  were  compared  according  to
heir  renal  function:  preserved  (nRF)  versus  impaired  (RF).
ndpoints
he  primary  endpoint  was  all-cause  mortality  at  1-year.
eath  was  deﬁned  as  death  from  any  cause.  The  secondary
ndpoints  were  major  adverse  cardiovascular  and  cere-
rovascular  events  (MACCE:  a  composite  of  cardiovascular
eath,  myocardial  infarction,  stroke  and  target  lesion  revas-
ularization  [TLR]),  TLR  and  Academic  Research  Consortium
eﬁnite  or  probable  stent  thrombosis  (ST)  at  1  year.
Death  was  adjudicated  as  cardiovascular  death  if,  when
atients  died  suddenly,  an  autopsy  failed  to  reveal  another
ause,  or  if  death  was  associated  with  documented  myocar-
ial  infarction  or  other  cardiac  causes,  such  as  congestive
eart  failure  and  arrhythmia.  Myocardial  infarction  was
eﬁned  as  recurrent  chest  pain  and/or  electrocardiogram
hanges  with  at  least  one  of  the  following  criteria:  cre-
tine  kinase  or  troponin  I  ≥  two  times  the  upper  limit  of
ormal  with  an  increase  of  >  50%  over  the  previous  value
nd/or  the  appearance  of  new  left  bundle  branch  block  or
ew  Q  waves.  Stroke  was  deﬁned  as  an  acute  neurological
eﬁcit  lasting  for  >  24  hours,  as  classiﬁed  by  a  physician,  with
upporting  information,  including  brain  images  and  neuro-
ogical/neurosurgical  evaluation.  Clinical  TLR  was  deﬁned
s  new  revascularization  of  the  index  lesion  mandated
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by  clinical  symptoms  or  documented  ischaemia.  ST  was
deﬁned  as  deﬁnite  or  probable  ST  according  to  the  Academic
Research  Consortium  criteria  [9].
One-year  follow-up  was  obtained  from  outpatient  clinic
visits,  review  of  medical  records  or  telephone  interview  with
the  patient  or  their  family.  Informed  consent  was  obtained
from  each  patient,  and  the  study  protocol  conforms  to  the
ethical  guidelines  of  the  1975  Declaration  of  Helsinki,  as
reﬂected  in  a  priori  approval  by  the  institution’s  human
research  committee.
Statistical analyses
Continuous  variables  are  expressed  as  means  ±  standard
deviations  and  were  compared  by  the  t-test.  Categorical
variables  are  expressed  as  numbers  and  percentages  and
were  compared  by  the  2 test.  Kaplan—Meier  curves  were
drawn  using  Prism  5  software  (GraphPad  Software,  Inc.,  La
Jolla,  CA,  USA).  Among  all  baseline  clinical  and  procedural
characteristics,  variables  with  a  P  value  <  0.05  in  univariate
analyses  were  included  in  multivariable  logistic  regression
models  to  determine  the  independent  factors  for  1-year
mortality  and  1-year  MACCE.  The  statistical  analyses  were
performed  with  SPSS  software  for  Windows,  version  15.0
(SPSS,  Inc.,  Chicago,  IL,  USA).  A  P  value  <  0.05  was  consid-
ered  to  indicate  statistical  signiﬁcance.
Results
Baseline characteristics
Among  5337  consecutive  patients  who  underwent  PCI  with
stent  in  our  institution,  1219  (23%),  1837  (34%)  and  2281
(43%)  patients  had  STEMI,  ACS  and  sCAD,  respectively.  Nearly
one  third  of  PCI  patients  had  RF  (27%);  among  them,  126  (9%)
had  dialysis,  156  (11%)  had  severe  RF  (CrCl  <  30  mL/min)  and
1176  (80%)  had  moderate  RF  (CrCl  30—60  mL/min).
Patients  with  RF  were  older  (74  vs.  62  years  old),  more
likely  to  be  women  (35%  vs.  17%)  and  had  more  hypertension
M
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Figure 1. Unadjusted 1-year clinical outcomes according to percutan
acute coronary syndrome; MACCE: major adverse cardiovascular and cere
infarction, stroke and target lesion revascularization); nRF: preserved
ST-segment elevation myocardial infarction; TLR: target lesion revascula557
72%  vs.  54%),  history  of  stroke  (10%  vs.  5%)  and  multivessel
isease  (60%  vs.  50%),  with  a  lower  rate  of  DES  use  (51%
s.  64%)  in  all  groups.  These  patients  were  less  likely  to  be
urrent  smokers  (13%  vs.  34%)  or  to  have  a  family  history  of
AD  (11%  vs.  21%)  (P  <  0.0001,  for  all  comparisons).
Baseline  clinical  and  procedural  characteristics  according
o  PCI  indication  and  renal  function  are  shown  in  Table  1;  23%
f  STEMI  patients  and  29%  of  both  ACS  and  sCAD  patients  had
F  (P  =  0.0002).  At  admission,  RF  patients  were  more  likely
o  present  with  out-of-hospital  cardiac  arrest  or  cardiogenic
hock  in  the  STEMI  and  ACS  groups.  The  radial  artery  was  the
ain  access  for  PCI  (4861,  91%),  although  radial  PCI  was  used
ess  frequently  in  STEMI  patients  with  RF  versus  nRF  (79%  vs.
2%;  P  <  0.0001).  In  the  overall  patient  population,  the  radial
pproach  was  less  accessible  in  RF  versus  nRF  patients  (88%
s.  92%;  P  <  0.0001).  In  STEMI  patients,  the  number  of  stents
mplanted  and  the  total  stent  length  were  slightly  higher,
hile  the  average  stent  diameter  was  lower  in  RF  than  in
RF  patients.
ne-year outcomes
ollow-up  was  completed  for  5236  (98.1%)  patients  at  1 year.
 total  of  101  patients  (1.9%)  among  5337  were  lost  to
ollow-up  because  of  the  inability  to  reach  them  (no  or
rong  phone  number,  no  clinical  visit),  the  person  of  trust
uring  hospitalization,  the  general  practitioner  or  the  car-
iologist,  and  after  checking  the  lack  of  a  death  certiﬁcate
n  their  birth  city  hall.  During  that  period,  486  (9%)  patients
ied,  348  (6.5%)  from  a  cardiovascular  cause,  815  (15%)  had
ACCE,  336  (6.3%)  had  TLR  and  95  (1.8%)  had  deﬁnite  or
robable  ST.  The  all-cause  1-year  mortality  rate  was  15%  in
TEMI  patients  compared  with  10%  in  ACS  patients  and  5%  in
CAD  patients  (P  <  0.0001).  One-year  outcomes  are  shown  in
ig.  1.Patients  with  RF  had  increased  all-cause  mortality  and
ACCE  rates  whatever  the  indication  for  PCI,  with  the  high-
st  event  rates  being  observed  in  STEMI  patients  (P  < 0.0001
or  all  comparisons).  RF  patients  with  STEMI  had  an  almost
eous coronary intervention indication and renal failure (RF). ACS:
brovascular events (composite of cardiovascular death, myocardial
 renal function; sCAD: stable CAD; ST: stent thrombosis; STEMI:
rization.
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Table  1  Baseline  patient  characteristics.
STEMI  (n  =  1219)  ACS  (n  =  1837)  sCAD  (n  =  2281)
RF
(n  =  278,
23%)
nRF
(n  =  941,
77%)
P  RF
(n  =  527,
29%)
nRF
(n  =  1310,
71%)
P  RF
(n  =  653,
29%)
nRF
(n  =  1628,
71%)
P
Age  (years)  74  ±  13  58  ±  12  <  0.0001  75  ±  10  61  ±  12  <  0.0001  73  ±  10  64  ±  10  <  0.0001
Men  161  (58)  772  (82)  <  0.0001  340  (64)  1072  (82)  <  0.0001  446  (68)  1376  (84)  <  0.0001
BMI  (kg/m2)  26  ±  13  27  ±  10  0.185  24  ±  4  27  ±  11  <  0.0001  25  ±  8  28  ±  17  <  0.0001
CrCl  (mL/min)  43  ±  12  108  ±  35  <  0.0001  40  ±  14  101  ±  32  <  0.0001  43  ±  14  94  ±  28  <  0.0001
Dialysis  5  (1.8)  —  —  57  (11)  —  —  64  (10)  —  —
Diabetes  65  (23)  163  (17)  0.023  186  (35)  321  (24)  <  0.0001  212  (32)  550  (34)  0.546
Dyslipidaemia  113  (41)  361  (38)  0.492  280  (53)  680  (52)  0.635  399  (61)  1047  (64)  0.150
Current  smoker  53  (19)  489  (52)  <  0.0001  74  (14)  473  (36)  <  0.0001  64  (10)  355  (22)  <  0.0001
Hypertension  168  (60)  368  (39)  <  0.0001  403  (76)  707  (54)  <  0.0001  482  (74)  1033  (63)  <  0.0001
Family  history  of
CAD
17  (6)  212  (22)  <  0.0001  52  (10)  282  (21)  <  0.0001  87  (13)  336  (21)  <  0.0001
History  of  MI 29  (10) 66  (7)  0.062  101  (19)  250  (19)  0.968  119  (18)  382  (23)  0.006
History  of  PCI  30  (11)  79  (8)  0.219  157  (29)  338  (26)  0.114  235  (36)  640  (39)  0.140
History  of  CABG  13  (5)  14  (1.5)  0.002  61  (12)  86  (7)  <  0.0001  60  (9)  157  (10)  0.738
History  of  stroke  19  (7)  26  (3)  0.002  67  (13)  71  (5)  <  0.0001  56  (9)  98  (6)  0.028
Cardiac  arrest  43  (15)  66  (7)  <  0.0001  12  (2.3)  10  (0.8)  0.007  0 (0)  0  (0)  —
Cardiogenic
shock
60  (22)  44  (5)  <  0.0001  17  (3.7)  18  (1.4)  0.009  0 (0)  0  (0)  —
Radial  access  220  (79)  865  (92)  <  0.0001  471  (89)  1209  (92)  0.043  589  (90)  1507  (93)  0.061
DES  52  (19)  382  (41)  <  0.0001  290  (55)  884  (67)  <  0.0001  403  (62)  1211  (74)  <  0.0001
Multivessel  CAD  169  (61)  420  (45)  <  0.0001  326  (62)  663  (51)  <  0.0001  378  (58)  856  (53)  0.022
Number  of
stents/patient
1.63  ±  0.88  1.49  ±  0.75  0.012  1.68  ±  0.95  1.67  ±  0.97  0.868  1.68  ±  0.93  1.62  ±  0.93  0.059
Average  stent
diame-
ter/patient
(mm)
2.82  ±  0.46  2.92  ±  0.47  0.001  2.83  ±  0.53  2.86  ±  0.51  0.301  2.81  ±  0.48  2.82  ±  0.46  0.796
Total  stent
length/patient
(mm)
30  ±  18  27  ±  16  0.035  28  ±  18  29  ±  20  0.308  27  ±  18  27  ±  19  0.891
Data are expressed as mean ± standard deviation or number (%); ACS: acute coronary syndrome; BMI: body mass index; BMS: bare-metal stent; CABG: coronary artery bypass graft; CAD:
coronary artery disease; CrCl: creatinine clearance; DES: drug-eluting stent; MI: myocardial infarction; nRF: no renal failure; PCI: percutaneous coronary intervention; RF: renal failure;
STEMI: ST-segment elevation myocardial infarction; sCAD: stable CAD.
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Figure 2. Kaplan—Meier survival estimates of 1-year mortality
according to percutaneous coronary intervention indication and
renal failure (RF). ACS: acute coronary syndrome; nRF: preserved
Figure 3. Relative risks of 1-year (a) all-cause mortality and (b)
MACCE, in patients with renal failure compared with preserved
renal function, stratiﬁed by percutaneous coronary intervention
indication. ACS: acute coronary syndrome; MACCE: major adverse
cardiovascular and cerebrovascular events (composite of cardio-
vascular death, myocardial infarction, stroke and target lesion
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trenal function; sCAD: stable CAD; STEMI: ST-segment elevation
myocardial infarction.
six-fold  higher  unadjusted  all-cause  mortality  rate  (41%  vs.
7.5%),  while  the  primary  endpoint  was  tripled  in  ACS  patients
(19%  vs.  6%)  and  sCAD  patients  (10%  vs.  3%)  compared  with
in  nRF  patients  (P  <  0.0001  for  all  comparisons).  Fig.  2  shows
1-year  all-cause  mortality  Kaplan—Meier  estimates  accord-
ing  to  PCI  indication  and  RF  (log  rank  P  <  0.0001).  The  rate
of  MACCE  was  also  higher  in  RF  patients  whatever  the  PCI
indication  (45%  vs.  15%  in  STEMI,  23%  vs.  14%  in  ACS  and
14%  vs.  9%  in  sCAD;  P  <  0.05  for  all).  All-cause  mortality
and  MACCE  rates  were  similar  in  STEMI-nRF  versus  sCAD-
RF  patients  (P  =  0.209  and  0.658,  respectively).  TLR  rates
(5.5—7.4%)  and  deﬁnite/probable  ST  (<  2.5%)  were  similar
whatever  the  indication  for  PCI  and  renal  function  (P  >  0.05
for  all  comparisons).
Among  patients  with  RF,  all-cause  mortality  and  MACCE
rates  were  lower  in  the  group  with  moderate  RF  (CrCl
30—60  mL/min)  than  in  the  groups  with  more  severe  RF
(CrCl  <  30  mL/min)  or  haemodialysis  (202  [17%],  50  [32%],  29
[23%],  P  <  0.0001  and  259  [22%],  45  [29%],  37  [29%],  P  =  0.042,
respectively).  However,  the  rates  of  ST  and  TLR  were  not  dif-
ferent  between  the  three  subgroups  (5  [0.4%],  1  [0.6%],  19
[1.5%],  P  =  0.084  and  72  (6.1%),  7  (4.5%),  12  (9.5%),  P  =  0.496,
respectively).  One-year  all-cause  mortality  Kaplan—Meier
survival  analysis  in  all  studied  patients  showed  better  sur-
vival  in  patients  with  moderate  RF  (log  rank  P  <  0.0001)  (data
not  shown).
Independent predictors of all-cause mortality
and MACCE
Using  multivariable  analyses,  RF  was  independently  asso-
ciated  with  all-cause  mortality  (odds  ratio  2.671,  95%
conﬁdence  interval  2.108—3.384;  P  <  0.0001)  and  MACCE
(odds  ratio  1.749,  95%  conﬁdence  interval  1.480—2.067;
P  <  0.0001)  in  the  entire  cohort  (Table  2).The  other  independent  predictors  of  all-cause  mortality
were  age,  diabetes,  history  of  stroke,  cardiogenic  shock,
multivessel  disease  and  total  stent  length,  whereas  sCAD,
t
•evascularization); sCAD: stable CAD; STEMI: ST-segment elevation
yocardial infarction.
yslipidaemia,  radial  access  for  PCI  and  DES  use  were  pre-
ictive  of  survival.
Diabetes,  cardiogenic  shock,  multivessel  disease  and
otal  stent  length  were  independently  associated  with
ACCE,  whereas  sCAD,  radial  access,  stent  diameter  and
ES  use  were  associated  with  survival.
Multivariable  analyses  were  also  done  by  PCI  indication
ubgroups  (STEMI,  ACS  and  sCAD  cohorts).  Relative  risks  of
eath  and  MACCE  in  patients  with  RF  were  found  to  be  more
han  doubled  in  STEMI  patients  compared  with  in  patients
ith  ACS  and  sCAD  (Fig.  3).
iscussion
n  a  large  population  of  consecutive  unselected  patients
reated  by  PCI  with  stent  in  an  experienced  centre,  we  found
hat:
RF  appears  to  be  an  independent  predictor  of  all-cause
mortality  and  MACCE  whatever  the  indication  for  PCI;
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Table  2  Independent  predictors  of  all-cause  mortality  at  1-year  follow-up  in  all  patients  and  in  three  percutaneous
coronary  intervention  cohorts.
Variables  Odds  ratio  95%  CI  P
All  patients
Age  1.018  1.008—1.028  <  0.0001
sCAD  0.531  0.398—0.709  <  0.0001
Diabetes  1.694  1.353—2.120  <  0.0001
Dyslipidaemia  0.779 0.628—0.965  0.022
Family  history  of  CAD 0.648 0.453—0.927 0.018
History  of  stroke 1.777 1.272—2.482 0.001
Cardiogenic  shock 9.780 6.360—15.037 <  0.0001
Radial  access  0.539  0.399—0.727  <  0.0001
Multivessel  CAD  1.299  1.038—1.625  0.022
Total  stent  length/patient  1.007  1.002—1013  0.011
DES  0.302  0.238—0.382  <  0.0001
Renal  failure 2.671 2.108—3.384 <  0.0001
STEMI
Total  stent  length/patient  1.019  1.007—1.030  0.001
Diabetes  1.581  1.007—2.483  0.046
History  of  MI  1.968  1.059—3.663  0.032
Cardiogenic  shock  7.880  4.646—13.363  <  0.0001
Radial  access  0.515  0.306—0.866  0.012
DES  0.182  0.101—0.326  <  0.0001
Renal  failure  5.326  3.627—7.821  <  0.0001
ACS
Age  1.018  1.002—1.034  0.023
Diabetes  1.785  1.262—2.526  0.001
History  of  stroke  1.787  1.102—2.898  0.019
Cardiogenic  shock  12.302  5.561—27.216  <  0.0001
Multivessel  CAD  1.748  1.225—2.493  0.002
Radial  access  0.519  0.321—0.837  0.007
vDES  0.353  0.251—0.497  <  0.0001
Renal  failure  2.144  1.465—3.140  <  0.0001
sCAD
Age  1.031  1.010—1.053  0.004
Diabetes  1.817  1.229—2.687  0.003
Family  history  of  CAD 0.429 0.195—0.943  0.035
DES  0.326  0.219—0.484  <  0.0001
Renal  failure 2.286 1.507—3.469  <  0.0001
ACS: acute coronary syndrome; CAD: coronary artery disease; CI: conﬁdence interval; DES: drug-eluting stent; MI: myocardial infarction;
PCI: percutaneous coronary intervention; sCAD: stable CAD; STEMI: ST-segment elevation myocardial infarction.
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aRF is  a  stronger  independent  predictor  of  death  and
MACCE  after  PCI  in  STEMI  patients  compared  with  in  ACS
and  sCAD  patients;
TLR  and  ST  rates  were  not  affected  by  renal  function;
the  cardiovascular  prognosis  of  RF  patients  undergoing  PCI
for  sCAD  was  as  poor  as  that  of  STEMI  patients  with  normal
renal  function.
The  ﬁndings  from  the  present  study  extend  the  current
nowledge  in  several  ways.  First,  this  study  compares  for
he  ﬁrst  time  the  effect  of  RF  on  all-cause  mortality  and
ther  outcomes  in  different  PCI  cohorts  (STEMI,  ACS  and
CAD).  Additionally,  clinical  trials  tend  to  exclude  patients
ith  renal  impairment  and  to  encourage  speciﬁc  care  pat-
erns,  thus  probably  underestimating  the  true  burden  and
everity  of  RF  associated  with  CAD.  Our  ‘‘real-life’’  study
t
d
s
tay  contribute  to  a  more  comprehensive  assessment  of  RF
n  the  PCI  population.
In this  study,  we  aimed  to  evaluate  the  inﬂuence  of  RF
n  all-cause  mortality  in  5337  consecutive  patients  treated
y  PCI  in  our  centre  within  6  years.  In  this  unselected  ‘‘all-
omers’’  population,  we  found  that  RF  was  independently
ssociated  with  a  striking  increase  in  1-year  all-cause  mor-
ality  in  all  patients  treated  with  PCI.  This  adverse  impact
f  RF  was  more  pronounced  in  STEMI  patients  (six-fold  unad-
usted  increase  in  all-cause  mortality  rate)  compared  with  in
CS  and/or  sCAD  patients  (three-fold  increase).  Even  after
djustment  for  other  important  baseline  prognostic  factors,
he  relative  risk  of  death  associated  with  RF  was  more  than
oubled  in  STEMI  patients  versus  ACS  and  sCAD  patients.  Our
tudy  echoes  the  recent  ﬁndings  of  Green  et  al.  [10],  Chary-
an  et  al.  [11]  and  Alexander  et  al.  [12], who  showed  an
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increased  rate  of  mortality  in  patients  with  RF  compared
with  in  patients  with  normal  renal  function  after  PCI.
RF  was  strongly  associated  with  1-year  mortality  and
exceeded  the  risk  associated  with  diabetes  mellitus  and
other  cardiovascular  risk  factors.  This  is  in  accordance  with
previous  studies  where  RF  has  been  found  to  be  associated
with  a  higher  long-term  mortality  [13,14].  More  speciﬁ-
cally,  STEMI  and  NSTEMI  patients  were  found  to  have  higher
9-month  all-cause  mortality  rate  in  case  of  RF  [15].  In  addi-
tion,  a  10  mL/min  decrease  in  creatinine  clearance  has  been
shown  to  contribute  as  much  as  a  10-year  increase  in  age
to  hospital  death  rates  [16].  Compared  with  other  reports,
mortality  was  high  in  our  unselected  PCI  population  [17,18].
This  may  be  explained  by  the  fact  that  patients  with  cardio-
genic  shock  were  not  excluded  in  our  study,  and  probably  by
an  increased  mortality  risk  in  non-randomized  and  all-comer
patients  in  a  reference  centre  compared  with  results  from
a  randomized  controlled  study.
The  deleterious  impact  of  RF  on  clinical  outcomes  in
CAD  appears  to  be  multifactorial.  RF  patients  were  older
and  more  likely  to  be  women,  to  have  hypertension,
to  have  a  history  of  coronary  artery  bypass  surgery  or
stroke  and  a  lower  proportion  of  implanted  DESs  in  all  PCI
cohorts;  they  were  also  more  likely  to  have  multivessel  dis-
ease,  out-of-hospital  cardiac  arrest  and  cardiogenic  shock
in  both  the  STEMI  and  ACS  groups.  Metabolic  abnormali-
ties  (including  hyperparathyroidism,  insulin  resistance  and
hyperuricaemia)  and  increased  oxidative  stress  observed  in
chronic  RF  may  predispose  to  the  cardiovascular  risk  excess
in  these  patients  [19].  Post-procedural  contrast-induced
nephropathy,  drug  toxicity  and  suboptimal  medical  treat-
ment  associated  with  the  management  of  patients  with  RF
may  also  contribute  to  this  poor  outcome  [20,21].
In  our  study,  we  conﬁrmed  a  lower  1-year  mortality  risk
in  sCAD  patients  compared  with  in  ACS  and  STEMI  patients.
Interestingly,  as  shown  with  diabetes  mellitus  by  Haffner
et  al.,  the  prognosis  of  RF  patients  with  sCAD  was  found
to  be  similar  to  that  of  STEMI  patients  without  RF,  out-
lining  the  signiﬁcant  contribution  of  RF  to  worse  outcome
[22].
The  radial  approach  was  predominant  in  all  PCI  groups,
although  less  accessible  in  RF  versus  nRF  patients  because  of
the  presence  of  arteriovenous  ﬁstula,  more  calciﬁed  and  tor-
tuous  vessels,  a  higher  proportion  of  women  and  older  age.
In  our  study,  we  found  that  radial  PCI  was  an  independent
predictor  of  survival  and  MACCE.  Previous  data  suggested
that  the  radial  approach  for  PCI  was  associated  with  lower
bleeding  complications  and  a  better  outcome  [23,24]. Our
results  suggest  that  the  radial  access  is  beneﬁcial  for  PCI
regardless  of  renal  function.
In  our  study,  TLR  at  1  year  was  similar  in  PCI  patients
whatever  the  PCI  indication  or  renal  function.  In  line  with
our  results,  RF  was  not  associated  with  increased  angio-
graphic  restenosis  and  TLR  at  1  year  after  either  BMS  or
DES  implantation  [25].  We  have  previously  published  that
the  use  of  DESs  in  non-selected  patients  with  RF  appears  to
be  at  least  as  effective  and  safe  as  BMSs  at  1  year  [26].
We  did  not  observe  any  excess  of  ST  at  1  year  between
RF  and  nRF  patients  in  all  PCI  patients  or  within  each  of
the  three  PCI  cohorts.  Similarly,  there  was  no  signiﬁcant
difference  in  ST  rates  between  NSTEMI  patients  on  or  with-
out  haemodialysis  [27].  This  issue  remains  controversial,  as
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ome  studies  have  previously  shown  that  RF  is  an  indepen-
ent  determinant  of  ST  [28].
tudy limitations and strengths
his  study  has  several  limitations  that  should  be  mentioned.
his  was  a  single-centre  non-randomized  registry.  Like  all
bservational  studies,  our  study  is  prone  to  biases  related
o  unmeasured  factors.  Bias  caused  by  unknown  variables
annot  be  eliminated.
We  did  not  possess  creatinine  values  taken  in  the  days
ollowing  PCI  or  information  regarding  contrast-induced
ephropathy.  Radiocontrast  toxicity  may  also  contribute  to
linical  deterioration  after  PCI,  especially  in  patients  with
F  [21].
In our  study,  data  on  medications  were  not  systematically
ollected,  especially  duration  of  dual  antiplatelet  therapy.
revious  studies  indicated  underutilization  of  known  cardio-
rotective  therapies  in  patients  with  RF,  and  more  frequent
rrors  in  dosing  when  used,  which  may  further  contribute
o  the  poor  outcomes  observed  in  this  group  [3,20].  Intense
ntiplatelet  therapy  may  be  associated  with  an  increased
isk  of  bleeding  complications  in  patients  with  RF  who
lready  have  a  higher  tendency  for  bleeding.
We  did  not  have  exact  data  regarding  the  rate  of  bleeding
omplications  and  the  need  for  transfusion.
The  strength  of  our  study  is  that  the  patients  were  all-
omers,  unselected  and  consecutive,  providing  real-world
ata  in  a  relatively  high  sample  size.  ‘‘Real-life’’  unselected
atient  populations  have  been  shown  to  differ  from  those
nrolled  in  clinical  trials.  Therefore,  clinical  data  are  less
iased  than  those  from  randomized  clinical  trials,  which  may
nder-represent  some  important  subgroups  of  patients,  such
s  the  elderly  and  patients  with  varying  degrees  of  renal
ysfunction.  Furthermore,  we  had  a  signiﬁcant  number  of
atients  with  RF  in  each  PCI  cohort,  enabling  a  detailed
nalysis  by  RF  and  PCI  indication.
onclusion
F  appears  to  be  strongly  associated  with  a  higher  risk
f  all-cause  mortality  and  MACCE  after  PCI,  but  not  with
n  increased  risk  of  repeat  revascularization  and  ST.  RF
s  a  stronger  independent  predictor  of  death  and  MACCE
fter  PCI  in  STEMI  patients  compared  with  in  ACS  and  sCAD
atients.  In  case  of  RF,  the  prognosis  after  elective  PCI  is
imilar  to  that  of  a patient  without  RF  treated  by  primary
CI  for  STEMI.
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